Advanced glycation end products and vascular structure and function

Current Hypertension Reports

Volumn 8, Issue 6, 2006, Pages 472-478

  Soldatos, Georgia ^a   Cooper, Mark Emmanuel ^b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; AMINOGUANIDINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; LOW DENSITY LIPOPROTEIN; LYSINE DERIVATIVE; METHYLGLYOXAL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL COMPLIANCE; BLOOD VESSEL FUNCTION; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; GENE FUNCTION; GLYCOSYLATION; HUMAN; NONHUMAN; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; SYSTOLIC HYPERTENSION;

ANIMALS; ANTIGENS, NEOPLASM; ATHEROSCLEROSIS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LYMPHOCYTE ACTIVATION; MITOGEN-ACTIVATED PROTEIN KINASES; THIAZOLES;

EID: 33751563879     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-006-0025-8     Document Type: Review

References (52)

1. King GL, Wakasaki H: Theoretical mechanisms by which hyperglycemia and insulin resistance could cause cardiovascular diseases in diabetes. Diabetes Care 1999, 22 Suppl 3:C31-C37.
2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993,329:977-986.
3. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
4. Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878.
5. Chaturvedi N, Sjolie AK, Stephenson JM, et al.: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998, 351:28-31.
6. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
7. de Vegt F, Dekker JM, Ruhe HG, et al.: Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999,42:926-931.
8. Cines DB, Pollak ES, Buck CA, et al.: Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998, 91:3527-3561.
9. Gu L, Okada Y, Clinton SK, et al.: Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998, 2:275-281.
10. Libby P, Aikawa M: New insights into plaque stabilisation by lipid lowering. Drugs 1998, 56(Suppl 1):9-13; discussion 33.
11. Libby P: Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001, 104:365-372.
12. Celentano DC, Frishman WH: Matrix metalloproteinases and coronary artery disease: a novel therapeutic target. J Clin Pharmacol 1997, 37:991-1000.
13. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988, 318:1315-1321.
14. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
15. Fu S, Fu MX, Baynes JW, et al.: Presence of dopa and amino acid hydroperoxides in proteins modified with advanced glycation end products (AGEs): amino acid oxidation products as a possible source of oxidative stress induced by AGE proteins. Biochem J 1998, 330(Pt 1):233-239.
16. Bucala R: Lipid and lipoprotein modification by advanced glycosylation end-products: role in atherosclerosis. Exp Physiol 1997, 82:327-337.
17. Brownlee M: Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995, 46:223-234.
18. Makita Z, Radoff S, Rayfield EJ, et al.: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991, 325:836-842.
19. Tanaka S, Avigad G, Brodsky B, et al.: Glycation induces expansion of the molecular packing of collagen. J Mol Biol 1988, 203:495-505.
20. Charonis AS, Reger LA, Dege JE, et al.: Laminin alterations after in vitro nonenzymatic glycosylation. Diabetes 1990, 39:807-814.
21. Laurent S, Boutouyrie P, Asmar R, et al.: Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001, 37:1236-1241.
22. Cruickshank K, Riste L, Anderson SG, et al.: Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002, 106:2085-2090.
23. Berry KL, Skyrme-Jones RA, Cameron JD, et al.: Systemic arterial compliance is reduced in young patients with IDDM. Am J Physiol 1999, 276(6 Pt 2):H1839-H1845.
24. Henry RM, Kostense PJ, Spijkerman AM, et al.: Arterial stiffness increases with deteriorating glucose tolerance status: the Hoorn Study. Circulation 2003, 107:2089-2095.
25. Schram MT, Henry RM, van Dijk RA, et al.: Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes: the Hoorn Study. Hypertension 2004, 43:176-181.
26. McVeigh GE, Morgan DJ, Finkelstein SM, et al.: Vascular abnormalities associated with long-term cigarette smoking identified by arterial waveform analysis. Am J Med 1997, 102:227-231.
27. Cohn JN, Finkelstein SM: Abnormalities of vascular compliance in hypertension, aging and heart failure. J Hypertens Suppl 1992, 10:S61-S64.
28. Leibovitz E, Hazanov N, Zimlichman R, et al.: Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia. Am J Hypertens 2001, 14(11 Pt 1):1096-1098.
29. Kimoto E, Shoji T, Shinohara K, et al.: Preferential stiffening of central over peripheral arteries in type 2 diabetes. Diabetes 2003, 52:448-452.
30. Brownlee M, Vlassara H, Kooney A, et al.: Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986, 232:1629-1632.
31. Wolffenbuttel BH, Boulanger CM, Crijns FR, et al.: Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci U S A 1998, 95:4630-4634.
32. Vaitkevicius PV, Lane M, Spurgeon H, et al.: A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Natl Acad Sci U S A 2001, 98:1171-1175.
33. Kass DA, Shapiro EP, Kawaguchi M, et al.: Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001, 104:1464-1470.
34. Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002, 287:2570-2581.
35. Schmidt AM, Yan SD, Yan SF, et al.: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001, 108:949-955.
36. Yeh CH, Sturgis L, Haidacher J, et al.: Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 2001, 50:1495-1504.
37. de Winther MP, Kanters E, Kraal G, et al.: Nuclear factor kappaB signaling in atherogenesis. Arterioscler Thromb Vasc Biol 2005, 25:904-914.
38. Wautier MP, Chappey O, Corda S, et al.: Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001, 280:E685-E694.
39. Leopold JA, Loscalzo J: Oxidative enzymopathies and vascular disease. Arterioscler Thromb Vasc Biol 2005, 25:1332-1340.
40. Park L, Raman KG, Lee KJ, et al.: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998, 4:1025-1031.
41. Bucciarelli LG, Wendt T, Qu W, et al.: RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002, 106:2827-2835.
42. Forbes JM, Yee LT, Thallas V, et al.: Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 2004, 53:1813-1823.
43. Sakata N, Imanaga Y, Meng J, et al.: Immunohistochemical localization of different epitopes of advanced glycation end products in human atherosclerotic lesions. Atherosclerosis 1998, 141:61-75.
44. Niwa T, Katsuzaki T, Miyazaki S, et al.: Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest 1997, 99:1272-1280.
45. Ritthaler U, Deng Y, Zhang Y, et al.: Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am J Pathol 1995, 146:688-694.
46. Cipollone F, Iezzi A, Fazia M, et al.: The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 2003, 108:1070-1077.
47. Burke AP, Kolodgie FD, Zieske A, et al.: Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol 2004, 24:1266-1271.
48. Kanauchi M, Tsujimoto N, Hashimoto T: Advanced glycation end products in nondiabetic patients with coronary artery disease. Diabetes Care 2001, 24:1620-1623.
49. Falcone C, Emanuele E, D'Angelo A, et al.: Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005, 25:1032-1037.
50. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853.
51. Esposito K, Giugliano D, Nappo F, et al.: Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004, 110:214-219.
52. Marfella R, Esposito K, Giunta R, et al.: Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia. Circulation 2000, 101:2247-2251.